骨髓纤维化的治疗——下一步何去何从？ - Suppr

Suppr

超能文献

Management of myelofibrosis--where next?

作者信息

Qureshi Moosa, Harrison Claire

出版信息

Expert Opin Pharmacother. 2011 Jul;12(10):1453-5. doi: 10.1517/14656566.2011.588948.

DOI:10.1517/14656566.2011.588948

PMID:21651445

Abstract

摘要

相似文献

Management of myelofibrosis--where next?

Expert Opin Pharmacother. 2011 Jul;12(10):1453-5. doi: 10.1517/14656566.2011.588948.

Therapeutic approaches in myelofibrosis.

Expert Opin Pharmacother. 2011 Jul;12(10):1597-611. doi: 10.1517/14656566.2011.568939. Epub 2011 Apr 4.

Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease.

Prog Clin Biol Res. 1984;154:3-17.

The myelodysplastic syndromes and myeloproliferative disorders.

Clin Lab Sci. 2004 Fall;17(4):223-34.

The spleen in myeloproliferative disorders.

Clin Haematol. 1983 Jun;12(2):505-16.

Myeloproliferative disorders.

Clin Geriatr Med. 1985 Nov;1(4):773-93.

[Osteomyelofibrosis as a prognostic factor in myeloproliferative diseases?].

Dtsch Med Wochenschr. 1993 May 28;118(21):804-5.

Janus kinase 2 inhibitors in myeloproliferative disorders.

Expert Opin Investig Drugs. 2011 Jan;20(1):41-59. doi: 10.1517/13543784.2011.538382. Epub 2010 Dec 4.

[Secondary myeloid splenomegalies and accompanying myeloid splenomegalies].

Nouv Presse Med. 1972 Apr 15;1(16):1063-4.

Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only.

Arch Intern Med. 1982 Aug;142(8):1533-7.

引用本文的文献

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.

Cochrane Database Syst Rev. 2015 Apr 10;2015(4):CD010298. doi: 10.1002/14651858.CD010298.pub2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Management of myelofibrosis--where next?

Expert Opin Pharmacother. 2011 Jul;12(10):1453-5. doi: 10.1517/14656566.2011.588948.

Therapeutic approaches in myelofibrosis.

Expert Opin Pharmacother. 2011 Jul;12(10):1597-611. doi: 10.1517/14656566.2011.568939. Epub 2011 Apr 4.

Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease.

Prog Clin Biol Res. 1984;154:3-17.

The myelodysplastic syndromes and myeloproliferative disorders.

Clin Lab Sci. 2004 Fall;17(4):223-34.

The spleen in myeloproliferative disorders.

Clin Haematol. 1983 Jun;12(2):505-16.

Myeloproliferative disorders.

Clin Geriatr Med. 1985 Nov;1(4):773-93.

[Osteomyelofibrosis as a prognostic factor in myeloproliferative diseases?].

Dtsch Med Wochenschr. 1993 May 28;118(21):804-5.

Janus kinase 2 inhibitors in myeloproliferative disorders.

Expert Opin Investig Drugs. 2011 Jan;20(1):41-59. doi: 10.1517/13543784.2011.538382. Epub 2010 Dec 4.

[Secondary myeloid splenomegalies and accompanying myeloid splenomegalies].

Nouv Presse Med. 1972 Apr 15;1(16):1063-4.

Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only.

Arch Intern Med. 1982 Aug;142(8):1533-7.

引用本文的文献

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.

Cochrane Database Syst Rev. 2015 Apr 10;2015(4):CD010298. doi: 10.1002/14651858.CD010298.pub2.